The stock of Jumei International Holding Ltd(ADR) (NYSE:JMEI) reached all time low today, Mar, 21 and still has $3.50 target or 4.00% below today’s $3.65 share price. This indicates more downside for the $521.08 million company. This technical setup was reported by Barchart.com. If the $3.50 PT is reached, the company will be worth $20.84 million less. About 527,974 shares traded or 38.17% up from the average. Jumei International Holding Ltd(ADR) (NYSE:JMEI) has declined 17.25% since August 12, 2016 and is downtrending. It has underperformed by 25.92% the S&P500.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The company has market cap of $511.52 million. The Firm is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It has a 36.94 P/E ratio. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Jumei International Holding Limited is an online retailer of beauty products. The company has market cap of $521.08 million. The Company’s sales formats consist of curated sales, online shopping mall and flash sales. It has a 62.66 P/E ratio. The Company’s Jumei Global sales channel is part of its curated sales format.
Analysts await Jumei International Holding Ltd(ADR) (NYSE:JMEI) to report earnings on May, 5.
Among 7 analysts covering Jumei International (NYSE:JMEI), 2 have Buy rating, 3 Sell and 2 Hold. Therefore 29% are positive. Jumei International had 8 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Jumei International Holding Ltd(ADR) (NYSE:JMEI) has “Underperform” rating given on Monday, November 23 by CLSA. Credit Agricole downgraded Jumei International Holding Ltd(ADR) (NYSE:JMEI) on Monday, November 23 to “Underperform” rating. The firm has “Neutral” rating given on Monday, November 2 by Goldman Sachs. The firm has “Neutral” rating by Credit Suisse given on Tuesday, August 25. The firm earned “Underweight” rating on Wednesday, April 6 by Morgan Stanley.
Analysts await Cytokinetics, Inc. (NASDAQ:CYTK) to report earnings on April, 27. They expect $0.07 EPS, up 122.58% or $0.38 from last year’s $-0.31 per share. CYTK’s profit will be $2.94M for 43.43 P/E if the $0.07 EPS becomes a reality. After $0.16 actual EPS reported by Cytokinetics, Inc. for the previous quarter, Wall Street now forecasts -56.25% negative EPS growth.
Bvf Inc Il holds 11.84% of its portfolio in Cytokinetics, Inc. for 4.85 million shares. Dafna Capital Management Llc owns 210,306 shares or 2.24% of their US portfolio. Moreover, Ironwood Investment Management Llc has 1.08% invested in the company for 121,360 shares. The Illinois-based Fortaleza Asset Management Inc has invested 0.53% in the stock. Globeflex Capital L P, a California-based fund reported 139,065 shares.
Since January 1, 0001, it had 0 insider purchases, and 1 sale for $69,643 activity.
About 205,268 shares traded. Cytokinetics, Inc. (NASDAQ:CYTK) has risen 2.88% since August 12, 2016 and is uptrending. It has underperformed by 5.79% the S&P500.
Ratings analysis reveals 100% of Cytokinetics’s analysts are positive. Out of 7 Wall Street analysts rating Cytokinetics, 7 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $14 while the high is $24. The stock’s average target of $19.86 is 63.32% above today’s ($12.16) share price. CYTK was included in 8 notes of analysts from July 24, 2015. FBR Capital maintained the shares of CYTK in report on Tuesday, November 10 with “Outperform” rating. The company was initiated on Friday, December 16 by Cantor Fitzgerald. As per Monday, November 9, the company rating was maintained by Roth Capital. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. As per Monday, February 6, the company rating was upgraded by Needham. MLV maintained Cytokinetics, Inc. (NASDAQ:CYTK) on Friday, July 24 with “Buy” rating. On Monday, November 9 the stock rating was maintained by TH Capital with “Buy”. Needham maintained it with “Buy” rating and $17 target in Wednesday, July 27 report.
